Related Experiment Video

Updated: Jan 31, 2026

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

14.0K

Intramyocardial bone marrow cell injection does not lead to functional improvement in patients with chronic ischaemic

I Mann1, C C S Tseng2, S F Rodrigo1

  • 1Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.

Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation
|December 21, 2018
PubMed

Insights

Bone marrow cell injection did not improve cardiac function in patients with chronic ischemic heart failure. This study found no significant benefits compared to placebo for heart function or clinical outcomes.

Area of Science:

  • Cardiology
  • Regenerative Medicine
  • Cell Therapy

Background:

  • Previous studies on bone marrow cell therapy for chronic heart failure yielded inconsistent results.
  • Chronic ischemic heart disease patients often have limited treatment options.

Purpose of the Study:

  • To assess the efficacy of intramyocardial injection of mononuclear bone marrow cells.
  • To evaluate treatment effects in patients with chronic ischemic heart failure and limited stress-inducible ischemia.

Main Methods:

  • A multicenter, randomized, placebo-controlled trial involving 39 patients.
  • Patients received either autologous bone marrow cell injection or placebo.
  • Left ventricular ejection fraction (LVEF) was the primary endpoint, assessed by SPECT over 12 months.

Main Results:

  • No significant difference in LVEF change between the cell and placebo groups at 3 and 12 months (P=0.47 and P=0.08).
  • Secondary endpoints, including ventricular volumes and myocardial perfusion, also showed no significant improvement.
  • A subgroup analysis of patients with stress-inducible ischemia revealed no benefit.

Conclusions:

  • Intramyocardial bone marrow cell injection is ineffective for improving cardiac function in severe chronic ischemic heart failure.
  • The therapy did not lead to improvements in functional or clinical parameters in the studied patient group.
Abstract

Keywords:
Bone marrow cellsChronic heart failureIschaemia

More Related Videos

Isolation and Intravenous Injection of Murine Bone Marrow Derived Monocytes09:21

Isolation and Intravenous Injection of Murine Bone Marrow Derived Monocytes

Published on: December 27, 2014

24.7K
Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis06:28

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Published on: November 10, 2023

4.0K

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
920
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.6K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
882
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
336
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
966
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
312